MedPath

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JUVE-X)

Phase 1
Recruiting
Conditions
Juvenile Idiopathic Arthritis
Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Registration Number
CTIS2023-506131-15-00
Lead Sponsor
Eli Lilly & Co.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
184
Inclusion Criteria

Participants must have completed a previous study of baricitinib for the treatment of JIA, Participants must have not developed an allergy to baricitinib

Exclusion Criteria

Participants must not have permanently stopped baricitinib in the prior study, Participants must have not developed an allergy to baricitinib

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath